Delving into the Latest Updates on Zhejiang Jinhua CONBA Bio-Pharm Co., Ltd. with Synapse

Overview

Tags

Infectious Diseases

Immune System Diseases

Skin and Musculoskeletal Diseases

Small molecule drug

Synthetic peptide

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	2
Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	3
Synthetic peptide	1

Top 5 Target	Count

1,3-beta-glucan synthase	1
PBPs(Bacterial penicillin-binding protein)	1
ATP1A1(Sodium/potassium-transporting ATPase alpha-1 chain)	1
P2X7 receptor(P2X purinoceptor 7)	1

[Translation] A single-center, randomized, open-label, single-dose, four-period, two-sequence, fully repeated crossover bioequivalence study to evaluate the bioequivalence of the test product, Rivaroxaban Tablets (strength: 20 mg), and the reference product, Xarelto® (strength: 20 mg), in healthy adult subjects in the fed state

主要研究目的：研究空腹状态下单次口服受试制剂利伐沙班片（规格：20 mg，浙江金华康恩贝生物制药有限公司生产）与参比制剂利伐沙班片（Xarelto®，规格：20 mg，Janssen Pharmaceuticals Inc生产）在健康受试者体内的药代动力学，评价餐后状态下口服两种制剂的生物等效性。次要研究目的：评估受试制剂利伐沙班片（规格：20 mg）和参比制剂利伐沙班片（Xarelto®，规格：20 mg）在健康受试者中的安全性。

[Translation]

The main purpose of the study is to study the pharmacokinetics of the test preparation rivaroxaban tablets (specification: 20 mg, produced by Zhejiang Jinhua Kangenbei Biopharmaceutical Co., Ltd.) and the reference preparation rivaroxaban tablets (Xarelto®, specification: 20 mg, produced by Janssen Pharmaceuticals Inc) in healthy subjects after a single oral administration in the fasting state, and to evaluate the bioequivalence of the two preparations after oral administration in the fed state. Secondary purpose of the study is to evaluate the safety of the test preparation rivaroxaban tablets (specification: 20 mg) and the reference preparation rivaroxaban tablets (Xarelto®, specification: 20 mg) in healthy subjects.

Start Date28 Jun 2024

Sponsor / Collaborator

Zhejiang Jinhua CONBA Bio-Pharm Co., Ltd.

CTR20241973 / Active, not recruitingNot Applicable

评估受试制剂利伐沙班片（规格：20 mg）与参比制剂Xarelto®（规格：20 mg）在健康成年受试者空腹状态下的单中心、随机、开放、单剂量、四周期、两序列、完全重复交叉生物等效性研究

[Translation] A single-center, randomized, open-label, single-dose, four-period, two-sequence, fully repeated crossover bioequivalence study to evaluate the test product, Rivaroxaban Tablets (strength: 20 mg), and the reference product, Xarelto® (strength: 20 mg), in healthy adult subjects under fasting conditions.

主要研究目的：研究空腹状态下单次口服受试制剂利伐沙班片（规格：20 mg，浙江金华康恩贝生物制药有限公司生产）与参比制剂利伐沙班片（Xarelto®，规格：20 mg，Janssen Pharmaceuticals Inc生产）在健康受试者体内的药代动力学，评价空腹状态下口服两种制剂的生物等效性。次要研究目的：评估受试制剂利伐沙班片（规格：20 mg）和参比制剂利伐沙班片（Xarelto®，规格：20 mg）在健康受试者中的安全性。

[Translation]

The main purpose of the study is to study the pharmacokinetics of a single oral dose of the test preparation rivaroxaban tablets (specification: 20 mg, produced by Zhejiang Jinhua Kangenbei Biopharmaceutical Co., Ltd.) and the reference preparation rivaroxaban tablets (Xarelto®, specification: 20 mg, produced by Janssen Pharmaceuticals Inc) in healthy subjects under fasting conditions, and to evaluate the bioequivalence of the two preparations when taken orally under fasting conditions. The secondary purpose of the study is to evaluate the safety of the test preparation rivaroxaban tablets (specification: 20 mg) and the reference preparation rivaroxaban tablets (Xarelto®, specification: 20 mg) in healthy subjects.

Start Date27 Jun 2024

Sponsor / Collaborator

Zhejiang Jinhua CONBA Bio-Pharm Co., Ltd.

CTR20241926 / Active, not recruitingNot Applicable

浙江金华康恩贝生物制药有限公司生产的布南色林片与持证商为Sumitomo Dainippon Pharma Co.，Ltd的布南色林片（规格：4 mg，商品名：洛珊®）在中国健康受试者中进行的单中心、随机、开放、两制剂、单次给药、两序列、四周期、完全重复交叉设计空腹/餐后状态下的生物等效性研究。

[Translation] A single-center, randomized, open-label, two-dose, single-dose, two-sequence, four-period, completely repeated crossover design bioequivalence study was conducted in healthy Chinese subjects in the fasting/fed state between Bunanserin Tablets produced by Zhejiang Jinhua Kangenbei Biopharmaceutical Co., Ltd. and Bunanserin Tablets (strength: 4 mg, trade name: Loxan®) whose licensee is Sumitomo Dainippon Pharma Co., Ltd.

浙江金华康恩贝生物制药有限公司生产的布南色林片与持证商为Sumitomo Dainippon Pharma Co.，Ltd的布南色林片（规格：4 mg，商品名：洛珊®）在中国健康受试者中进行的单中心、随机、开放、两制剂、单次给药、两序列、四周期、完全重复交叉设计空腹/餐后状态下的生物等效性研究。

[Translation]

A single-center, randomized, open-label, two-dose, single-dose, two-sequence, four-period, completely repeated crossover design bioequivalence study was conducted in healthy Chinese subjects in the fasting/fed state between Bunanserin Tablets produced by Zhejiang Jinhua Kangenbei Biopharmaceutical Co., Ltd. and Bunanserin Tablets (strength: 4 mg, trade name: Loxan®) whose licensee is Sumitomo Dainippon Pharma Co., Ltd.

Start Date25 Jun 2024

Sponsor / Collaborator

Zhejiang Jinhua CONBA Bio-Pharm Co., Ltd.

100 Clinical Results associated with Zhejiang Jinhua CONBA Bio-Pharm Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Zhejiang Jinhua CONBA Bio-Pharm Co., Ltd.

Login to view more data

20

Literatures (Medical) associated with Zhejiang Jinhua CONBA Bio-Pharm Co., Ltd.

Zhongguo Yiyao Gongye Zazhi

Synthesis of tetrandrine

Author: Zheng, Yufei ; Ying, Zhihong ; Jiang, Xiaolin ; Fu, Zhihui ; Yan, Tuming

Tetrandrine, a non-selective calcium channel blocker, was prepared by the reaction of demethyl tetrandrine with di-Me sulfate in the presence of 1, 5-diazabicyclo[4.3.0]non-5-ene (DBN) with a yield over 70% and purity of 99.5%. The reaction was simple and complete.The resource utilization of Stephania tetrandra was increased.

Zhongguo Yaowu Huaxue Zazhi

Improved synthesis of panipenem

Author: Yang, Jianguo ; Fang, Huizhen ; Jin, Qingping ; Liu, Dan ; Huang, Weilian

Panipenem I is a new carbapenem antibiotics for the treatment of inflammation caused by sensitive bacteria.Its synthetic route was optimized and improved.The target compound was obtained from p-nitrobenzyl alc. as starting material by esterification, enolization, concentration with 4-AA, cyclization to intermediate, then concentration with (S)-1-(p-nitrobenzyloxycarbonyl) ethylimino-3-mercaptopyrrolidine and deprotection reactions.The overall yield was 24.5% (based on p-nitrobenzyl alc.) via six reaction.The chem. structure of panipenem were characterized by MS, NMR and element anal.Compared with the synthetic process reported in the literature, this synthetic route is simple and suitable for industrialized production with lower cost, lower pollution and higher yield.

Huagong Shengchan Yu Jishu

Research progresses on high-speed countercurrent chromatography

Author: Wang, Minyan ; Li, Yi ; Ye, Longzhong ; Chen, Xiu

A review.Recent research progresses on high-speed countercurrent chromatog. (HSCCC) were reviewed.Two-phase solvent systems in HSCCC are summarized.A number of application examples of HSCCC in natural products, antibiotics and proteins were emphatically given.

100 Deals associated with Zhejiang Jinhua CONBA Bio-Pharm Co., Ltd.

Login to view more data

100 Translational Medicine associated with Zhejiang Jinhua CONBA Bio-Pharm Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

2

Approved

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Digitoxin ( ATP1A1 )	Arrhythmias, Cardiac More	Approved
Azlocillin Sodium ( PBPs )	Bacterial Infections More	Approved
Anidulafungin ( 1,3-beta-glucan synthase )	-	Phase 1
EVT-401 ( P2X7 receptor )	Rheumatoid Arthritis More	Phase 1